Advertisement

A New Membrane Protein Associated with Resistance to cis-Platinum and Methotrexate

  • Samuel D. Bernal
  • Yuk-Chor Wong
  • Mika Kakefuda
  • A. Godofredo Urbano

Abstract

The mechanisms of resistance to alkylating drugs include defective transport across the cell membrane, intracellular bio-transformation to inactivate the drug, and repair of damaged DNA (Goldenberg et al, 1979; Hilton, 1984; Vistica et al, 1978). Thus, cis-diaminodichloroplatinum (CDDP)-resistant cell lines were found to have elevated glutathione (Hamilton et al, 1985; Hromas et al, 1987); increased metallothionein (Andrews et al, 1985); and increased DNA repair (Behrens et al, 1987). However, defects in membrane transport were also found to be an important mechanism of CDDP resistance. In ovarian carcinoma cells that were only 3.3 fold resistant to CDDP, showed 50% reduction in CDDP accumulation in a wide range of CDDP concentrations tested (Andrews et al, 1988). The rate of CDDP efflux and metabolic conversion of CDDP in these cells were unchanged. Decreased CDDP accumulation was an important mechanism of resistance that was expressed early in the development of CDDP resistance. In a human carcinoma cell line resistant to CDDP, there was at least a 3 fold decrease in the intracellular uptake and 10 fold decrease in nuclear accumulation of radioactive platinum complex(195mPt-CDDP) compared to the parent line (Teicher et al, 1987). The resistant cells did not differ in GSH (reduced glutathione) from the sensitive cells. The kinetics of release of radioactive CDDP was unchanged, suggesting that drug uptake was responsible for differences in drug accumulation.

Keywords

Resistant Cell Line Human Ovarian Carcinoma Cell Human Carcinoma Cell Line CDDP Resistance Human Squamous Carcinoma Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andrews PA, Murphy MP, and Howell SB, 1985, Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res. 45:6250–3.PubMedGoogle Scholar
  2. Andrews P, Velury S, Mann S, and Howell SB, 1988, Cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 48:67–73.Google Scholar
  3. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC and Ozols RF, 1987, Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47:414–8.PubMedGoogle Scholar
  4. Bernal SD, Weinberg K, Kakefuda M, Stahel R, O’Hara C, and Wong YC, 1988, Membrane antigens of human bronchial epithelial cells. In Vitro 24:117–25.Google Scholar
  5. Bernal SD, Speak JA, Boeheim K, Dreyfuss AI, Wright JE, Teicher BA, Rosowsky A, Tsao SW, and Wong YC, 1990, Reduced membrane protein associated with resistance of human squamous carcinoma cells to methotrexate and cis-platinum. Mol Cell Biochem 95:61–70.PubMedCrossRefGoogle Scholar
  6. Bird JE, Walser MM, and Quebbemann AJ, 1984, Protective effect of organic cation transport inhibitors on cis-diamminedichloroplatinum-induced nephrotoxicity. J Pharmacol Exp Ther 231:752–8.PubMedGoogle Scholar
  7. Boeheim K, Speak JA, Frei E III, and Bernal SD, 1985, SQM1 antibody defines a surface membrane antigen in squamous carcinoma of the head and neck. Int J Cancer 36:137–43.PubMedCrossRefGoogle Scholar
  8. Byfield JE and Calabro-Jones PM, 1981, Carrier-dependent and carrier-independent transport of anti-cancer alkyating agents. Nature 294:281–3.PubMedCrossRefGoogle Scholar
  9. Canada RG, 1986, Terbium fluorescence studies of cisplatin binding to GH3/B6 pituitary tumor cells. Biocim Biophys Acta 887:29–34.CrossRefGoogle Scholar
  10. Chou PY and Fasman GD, 1978, Empirical predictions of protein conformation. Annu Rev Biochem. 47:251–76.PubMedCrossRefGoogle Scholar
  11. Derynck R, Roberts AB, Winkler ME, Chen EY, and Goeddel DV, 1984, Human transforming growth factor-alpha: precursor structure and expression in E. coli. Cell 38:287–97.PubMedCrossRefGoogle Scholar
  12. Doolittle RF, 1984, Fibrinogen and fibrin. Annu Rev Biochem 53:195–229.PubMedCrossRefGoogle Scholar
  13. Dornish JM and Petersen EO, 1985, Protection from cis-dichlorodiammineplatinum-induced cell inactivation by aldehydes involves cell membrane amino groups. Cancer Lett 29:235–43.PubMedCrossRefGoogle Scholar
  14. Gale GR, Rosenblum MG, Atkins LM, Walker EM Jr, Gale GR, 1973, Antileukemic synergism between cyclophosphamide and an antitumor platinum compound. Res Commun Chem Pathol Pharmacol 6:419–25.PubMedGoogle Scholar
  15. Goldenberg GJ, Lam HY, and Begleiter A, 1979, Active carrier-mediated transport of melphalan by two separate amino acid transport systems in LPC-1 plasmacytoma cells in vitro. J Biol Chem 254:1057–64.PubMedGoogle Scholar
  16. Gray A, Dull TJ, and Ullrich A, 1983, Nucleotide sequence of epidermal growth factor cDNA predicts a 128,000-molecular weight protein precursor. Nature 303:722–5.PubMedCrossRefGoogle Scholar
  17. Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, Grotzinger KR, McKoy WM, Young RC, and Ozols RF, 1985, Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and-sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 34:2583–6.PubMedCrossRefGoogle Scholar
  18. Hilton J, 1984, Deoxyribonucleic acid crosslinking by 4-hydroperoxycyclophosphamide in cyclophosphamide-sensitive and-resistant L1210 cells. Biochem Pharmacol 33:1867–72.PubMedCrossRefGoogle Scholar
  19. Hromas RA, Andrews PA, Murphy MP, and Burns CP, 1987, Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells. Cancer Lett 34:9–13.PubMedCrossRefGoogle Scholar
  20. James DE, Brown R, Navarro J and Pilch PF, 1988, Insulin-regulatable tissues express a unique insulin-sensitive glucose transport protein. Nature 333:183–5.PubMedCrossRefGoogle Scholar
  21. Karlin S, Blaisdell BE, Mocarski ES, and Brendel V, 1989, A method to identify distinctive charge configurations in protein sequences, with application to human herpesvirus polypeptides. J Mol Biol 205:165–77.PubMedCrossRefGoogle Scholar
  22. Kozak M, 1984, Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs. Nucleic Acids Res. 12:857–72.PubMedCrossRefGoogle Scholar
  23. Proudfoot NJ and Brownlee GG, 1976, 3′ non-coding region sequences in eukaryotic messenger RNA. Nature 263:211–4.PubMedCrossRefGoogle Scholar
  24. Rosowsky A, Wright J, Cucchi C, et al, 1987, Collateral MTX resistance in cultured human head and neck carcinoma cells selected for resistance to cis-DDP. Cancer Res 47: 5913–8.PubMedGoogle Scholar
  25. Safirstein R, Miller P, and Guttenplan JB, 1984, Uptake and metabolism of cisplatin by rat kidney. Kidney Int 25:753–8.PubMedCrossRefGoogle Scholar
  26. Sanger F, Nicklen S, and Coulson AR, 1977, DNA sequencing with chain-terminating inhibitors. PNAS 74:5463–7.PubMedCrossRefGoogle Scholar
  27. Shionoya S, Lu Y and Scanlon KJ, 1986, Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-Diamminedichloroplatinum(II). Cancer Res 46:3445–8.PubMedGoogle Scholar
  28. Simpson IA and Cushman SW, 1986, Hormonal reglation of mammalian glucose transport. Annu Rev Biochem 55:1059–89.PubMedCrossRefGoogle Scholar
  29. Stoolman LM, 1989, Adhesion molecules controlling lymphocyte migration. Cell 56:907–10.PubMedCrossRefGoogle Scholar
  30. Stroobant P, Rice AP, Gullick WJ, Cheng DJ, Kerr Im and Waterfield MD, 1985, Purification and characterization of caccinia virus growth factor. Cell 42:383–93.PubMedCrossRefGoogle Scholar
  31. Suzuki K and Kono T, 1980, Evidence that insulin causes translocation of glucose transport activity to the plasma membrane from an intracellular storage site PNAS 77:2542–5.Google Scholar
  32. Teicher BA, Cucchi CA, Lee JB, Flatow JL, Rosowsky A, and Frei E 3d, 1986, Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines. Cancer Res. 46:4379–83.PubMedGoogle Scholar
  33. Teicher BA, Holden SA, Kelly MJ, Shea TC, Cucchi CA, Rosowsky A, Henner WD, and Frei E 3d, 1987, Characterization of a human squamous carcinoma cell line resistant to CDDP. Cancer Res 47:388–392.PubMedGoogle Scholar
  34. Tsao SW, Chew EC, Yam HF, and Bernal SD, 1990, Ultrastructural localization of a new surface membrane protein (SQM1) related to squamous differentiation. In Vivo 3:367–74.Google Scholar
  35. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J et al, 1984, Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309:418–25.PubMedCrossRefGoogle Scholar
  36. Vistica DT, Toal JN, and Rabinovitz M, 1978, Amino acid-conferred protection against melphalan—characterization of melphalan transport and correlation of uptake with cytotoxicity in cultured L1210 murine leukemia cells. Biochem Pharmacol 27:2865–70.PubMedCrossRefGoogle Scholar
  37. von Heijne G, 1984, Analysis of the distribution of charged residues in the N-terminal region of signal sequences: implications for protein export in prokaryotic and eukaryotic cells. EMBO J 3:2315–8.Google Scholar
  38. Wharton KA, Johansen KM, Xu T, Artavanis-Tsakonas S, 1985, Nucleotide sequence from the neurogenic locus notch implies a gene product that shares homology with proteins containing EGF-like repeats. Cell 43:567–81.PubMedCrossRefGoogle Scholar
  39. Williams PD and Hottendorf GH, 1985, Effect of cisplatin on organic ion transport in membrane vesicles from rat kidney cortex. Cancer Treat Rep 69:875–80.PubMedGoogle Scholar
  40. Wong YC, Tsao SW, Kakefuda M, and Bernal SD, 1990, cDNA cloning of a novel cell adhesion protein expressed in human squamous carcinoma cells. Biochem Biophys Res Comm 166:984–92.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Samuel D. Bernal
    • 1
  • Yuk-Chor Wong
    • 1
  • Mika Kakefuda
    • 1
  • A. Godofredo Urbano
    • 1
  1. 1.University Hospital Section of Medical Oncology BostonUniversity Medical CenterBostonUSA

Personalised recommendations